Stocktoria
INOVIO PHARMACEUTICALS, INC. INO
INOVIO PHARMACEUTICALS, INC. (INO) earns a Piotroski F-score of 0/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $65,343 at a -130000.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 0/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| INO | INOVIO PHARMACEUTICALS, INC. | 0/9 | — | — | — |
| CNTB | Connect Biopharma Holdings Ltd | 1/9 | — | — | -99.8% |
| AVTX | Avalo Therapeutics, Inc. | 1/9 | -8.95 | — | — |
| SILO | Silo Pharma, Inc. | 2/9 | -1.23 | — | — |
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
| IXHL | Incannex Healthcare Inc. | 2/9 | — | — | — |
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
About INOVIO PHARMACEUTICALS, INC.
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
FAQ
Is INO financially healthy?
INOVIO PHARMACEUTICALS, INC.'s Piotroski F-score is 0/9 (8–9 is excellent, 0–3 weak).
Does INO pay a dividend?
No, INOVIO PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is INO?
In FY2025, INOVIO PHARMACEUTICALS, INC. had a net margin of -130000.0% and a return on equity of -352.5%.
What is the analyst price target for INO?
The average Wall-Street price target for INOVIO PHARMACEUTICALS, INC. is $5.83, about 656.5% above the recent price, from 4 analysts.
Is INO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on INOVIO PHARMACEUTICALS, INC.: a Piotroski F-score of 0/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.